Home Page > Responses to April 3, 2008 letter

Responses to April 3, 2008 letter to 35 groups in regard to generic versions of biologic products

May 2, 2008	AARP
May 2, 2008	AFL-CIO
May 2, 2008	American Society of Clinical Oncology
May 2, 2008	Amgen
May 2, 2008	Association of American Universities
May 2, 2008	Barr Pharmaceuticals, Inc.
May 2, 2008	Biogen
May 2, 2008	Biotechnology Industry Organization
May 2, 2008	California Healthcare Institute
April 21, 2008	Cell Therapeutics, Inc.
May 2, 2008	Coalition for a Competitive Pharmaceutical Market
May 2, 2008	Consumers Union
May 2, 2008	Federal Trade Commission
April 30, 2008	General Motors
	Genetech
May 6, 2008	GlycoMimetics, Inc.
	GPHA
April 29, 2008	Insmed Incorporated
	Johnson & Johnson
May 2, 2008	Millennium Pharmaceuticals, Inc.
May 2, 2008	Mylan Labs
	National Governors Association
	National MS Society
May 2, 2008	National Organization of Rare Disorders
May 2, 2008	National Venture Capital Association
May 1, 2008	Novartis Corporation
May 2, 2008	PhRMA
	Teva Pharmaceuticals
May 2, 2008	Vertex Pharmaceuticals Incorporated